Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2012

Promega Continues Expanding in China

  • Promega opened a new facility in Shanghai for its China operations. The new site replaces an existing molecular biology reagent production site. It also provides additional research, development, and cGMP manufacturing capabilities for molecular diagnostics products for the Chinese market.

    The new facility is called Shanghai Promega Life Science Center. The building was purchased in June and has since been equipped for the manufacture of molecular biology and molecular diagnostic reagents.

    “China is an integral part of Promega’s manufacturing and business operations,” says Promega CEO Bill Linton. “In 1985, Promega and two Chinese partners established Sino-American Biotechnology Corporation (SABC), the first China-U.S. biotech joint venture in China. This recent investment in the new Shanghai cGMP manufacturing facility represents Promega’s continued commitment to life science in China.” Among its 15 global branches, Promega also has a sales and marketing branch in Beijing.

    Including this new facility, Promega has five manufacturing sites worldwide. Together these facilities manufacture biological and chemical reagents and instruments used in both life science research and molecular diagnostics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »